NEW YORK (GenomeWeb) – Intermountain Healthcare has entered into an agreement to offer its ICG100 cancer gene panel in Southeast Asia in collaboration with Singapore-based molecular diagnostics firm Asia Genomics, the partners announced yesterday.
ICG100 is a next-generation sequencing test based on a set of 100 genes that are analyzed for mutations that can help guide a cancer patient's treatment regimen. Intermountain began offering the test in mid-2013 for patients with Stage IV metastatic disease, but later expanded the service to late-stage patients with refractory cancer through its Intermountain Precision Genomics in-house lab.
Under their arrangement, Asia Genomics will contract with Intermountain Precision Genomics to offer ICG100 to its Southeast Asian customers. Additional terms of the deal were not disclosed.
"We are excited to be the first value-adding partner with Intermountain Precision Genomics outside of the US," Asia Genomics Founder and CEO Wong Mun-Yew said in a statement. "Leveraging Intermountain Precision Genomics' years of experience in cancer research, diagnosis, and treatment, we aim to improve survival and quality of life for cancer patients in Asia."